Get Started with Nozin® Programs

Professional Healthcare

MRSA | MSSA colonization risk mitigation solutions

Personal Use

Buy Nozin®

Nozin® Nasal Sanitizer® antiseptic helps reduce the risk of infection

Increased Risk of HAIs and the Case for Patient Decolonization

WHITEPAPER

The pandemic has led to the increased adoption of innovative technology in many hospitals to help ensure the safety of patients and staff.

READ NOW

Nozin® awarded among Best Infection Prevention Products by Newsweek and The Leapfrog Group for second consecutive year.

Read more »

Featured Webinar

Taking a new approach to HAIs in the COVID-19 Era

Summary

The COVID-19 pandemic has caused a diversion of resources, increasing the risk of HAIs. During this time, hospitals were challenged to rethink protocols to enhance the safety of patients and staff.

Learn More

Watch Now

THE PRESENTERS
John Willimann
CEO & Co-founder, Nozin

Sue Barnes, RN, CIC, FAPIC
IP Clinical Consultant

play

Words of a Champion

Making a difference in patient care.

Anita Mullen
RN, BSN, Infection Preventionist

play

Nozin 360 Healthcare

Better Care. Lower Costs.

play

Innovative Strategies

Reducing Infection Risk through Antiseptic-based Nasal Decolonization

Maureen Spencer
RN, M.Ed., CIC, FAPIC

Help protect your patients against infection with

Nasal Decolonization

Evidence shows nasal bacteria are a primary component in the spread of infection. Nozin® Nasal Sanitizer® antiseptic can help reduce the risk without antibiotics, improve quality of care & lower costs.

Reduce CP Responsibly

Learn More
CLINICALLY PROVEN

Nozin IP Programs

Reduce SSI

The most comprehensive program to help reduce Surgical Site Infections (SSI).

ICU Decolonization

Universal, safe, daily nasal decolonization is now possible.

Replace MRSA CP

Safely replace MRSA CP isolation, lower infections and Reduce costs.

Reduce Risk of Infection • Improve Patient Care • Lower Costs
View All Programs
View All Testimonials

Evidence

Evidence shows that nasal bacteria are a primary component in the spread of infection.

%

30% of population carry staph aureus in the nose⁸

%

80% of wound infections traced by DNA to bacteria in the patients’ own nose⁹

%

44% reduction in ICU infections with universal nasal and skin decolonization³

%

81% infection reduction with Nozin 360™ added to an existing IP bundle²

Health Professionals:
Request a comprehensive analysis of your MRSA & MSSA colonization risk mitigation protocols today.

© 2004-2021 Global Life Technologies Corp. All rights reserved. Nozin® Nasal Sanitizer® antiseptic is an OTC topical antiseptic drug and no claim is made that it has an effect on any specific disease. | Patent Nos.